Document Detail


Effect of immunoadsorption on refractory idiopathic focal and segmental glomerulosclerosis.
MedLine Citation:
PMID:  17120233     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A case of a young adult with refractory nephrotic syndrome due to focal segmental glomerulosclerosis is reported. Several treatments had been used without success including steroids, cyclophosphamide, cyclosporine A, tacrolimus, and mycophenolate mofetil. Immunoadsorption was performed as a last resort to manage the nephrotic syndrome, which led to a drastic urinary protein reduction. We review the literature supporting immunoadsorption in primary focal segmental glomerulosclerosis.
Authors:
Christian Kuhn; Andrea Kuhn; Silke Markau; Uta Kästner; Bernd Osten
Related Documents :
15779663 - Arbitrarily primed polymerase chain reaction for fingerprinting the genotype identifica...
4279123 - Nephrotic syndrome in chronic lymphocytic leukaemia.
479253 - Factors in the development of the spinal stenosis syndrome.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  Journal of clinical apheresis     Volume:  21     ISSN:  0733-2459     ISO Abbreviation:  J Clin Apher     Publication Date:  2006 Dec 
Date Detail:
Created Date:  2006-12-26     Completed Date:  2007-03-01     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8216305     Medline TA:  J Clin Apher     Country:  United States    
Other Details:
Languages:  eng     Pagination:  266-70     Citation Subset:  IM    
Affiliation:
Department of Internal Medicine II, University-Hospital Halle-Kröllwitz, Halle, Germany. christian.kuhn@medizin.uni-halle.de
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Anemia, Megaloblastic / chemically induced
Angiotensin II Type 1 Receptor Blockers / therapeutic use
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Azathioprine / adverse effects,  therapeutic use
Blood Proteins / chemistry
Combined Modality Therapy
Cyclophosphamide / therapeutic use
Drug Resistance
Glomerulosclerosis, Focal Segmental / complications,  therapy*
Humans
Immunosorbent Techniques*
Immunosuppressive Agents / adverse effects,  therapeutic use
Male
Mycophenolic Acid / analogs & derivatives,  therapeutic use
Nephrotic Syndrome / etiology
Plasmapheresis*
Proteinuria / etiology
Sepharose / chemistry
Staphylococcal Protein A / chemistry
Tacrolimus / therapeutic use
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Blood Proteins; 0/Immunosuppressive Agents; 0/Staphylococcal Protein A; 109581-93-3/Tacrolimus; 128794-94-5/mycophenolate mofetil; 24280-93-1/Mycophenolic Acid; 446-86-6/Azathioprine; 50-18-0/Cyclophosphamide; 9012-36-6/Sepharose

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Optimization of the concentration of autologous serum for generation of leukemic dendritic cells fro...
Next Document:  Plasma vitamin values and antiepileptic therapy: case reports of pregnancy outcomes affected by a ne...